Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 3 20Phase 1 10Phase NA 8Phase 2/3 6Phase 1/2 6Phase EARLY_PHASE1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Lymphoid 1Head & Neck 1

Conditions

Fallopian Tube Neoplasms 2Ovarian Neoplasms 1

Interventions

olaparib 6Specimen Handling 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 4Carboplatin 4pembrolizumab 3fludarabine 3X-Rays 3Taxes 3Metformin 3Letrozole 3Fluorodeoxyglucose F18 3Biopsy 3Aspirin 3niraparib 2Tirzepatide 2Radiotherapy 2Propranolol 2Platinum 2Pafolacianine 2Oncolytic Virotherapy 2Hysterectomy 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorescein 2Drug Therapy 2Doxorubicin 2Cytoreduction Surgical Procedures 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Drug Therapy × Gynecologic × Clear all
NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01504126 2019-08-29

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
32 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡